Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic

Posted on March 06 2017 by J Seabrook

Results of the study with the blood test Epi proColon® is now published in the journal of “Cancer Treatment and Research Communications”. Read more

Laboratory Developed Tests Roadmap and IVD Vendors

Posted on December 13 2016 by J Seabrook

MPLN follows a development process for laboratory developed tests. A phased approach is useful for organizing and assessing the performance of an assay. 

Read more


Concordance of three different PD-L1 diagnostic tests - update

Posted on December 07 2016 by J Seabrook

Concordance of three different PD-L1 diagnostic assays (1)

MPLN’s PD-L1 assay, the Ventana SP263, was included in the concordance study of three PD-L1 Diagnostic Tests by AstraZeneca and results reported at Read more

CAP Today Reports on Epi proColon Assay for Colon Cancer Screening

Posted on December 06 2016 by J Seabrook

A recent article by Anne Paxton in CAP Today (November 2016)  discusses the FDA approval of the Epigenomics Epi proColon® assay for colon cancer screening. MPLN's Dr. Nicholas Potter explains the series of events and the study data from…
Read more


MPLN presents IgVH NGS at AMP 2016

Posted on November 21 2016 by J Seabrook

Genomics team members from MPLN, Inc. including Isabel Hubbard, M.Sc., and Drs. Alice Layton and Bevan Tandon recently presented at the 2016 Association for Molecular Pathology annual meeting on the relative utility of Next Generation Sequencing for…
Read more

1 2 3 4 5 6 7 8